| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | MS-275 | FIMM | pan-cancer | AAC | 0.4 | 0.005 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | JQ12 | GDSC1000 | pan-cancer | AAC | -0.095 | 0.006 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.42 | 0.007 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | -0.088 | 0.007 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.44 | 0.008 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.084 | 0.008 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.009 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.009 |